ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

Research

Infectious diseases · Clin Infect Dis · 2026-10-28

Secondary analysis of two pooled phase 3 trials in females with uncomplicated UTI: therapeutic success favoured gepotidacin over nitrofurantoin by 9.6% (susceptible) and 20.8% (non-susceptible uropathogens); clinical success gaps non-significant.

Secondary analysis
Sheets et al. Subgroup Analysis of Pooled Phase 3 Efficacy Data From Two Randomized Trials of Gepotidacin Versus Nitrofurantoin in Uncomplicated Urinary Tract Infections (EAGLE-2 and EAGLE-3) Including Participants With Uropathogens Not-Susceptible to Nitrofurantoin
Infectious diseases · Clin Infect Dis · 2026-04-30

Secondary pooled analysis of two phase 3 RCTs (3136 participants) in uncomplicated UTI: gepotidacin and nitrofurantoin gave similar early symptom relief; 53.2% vs 53.6% with moderate-severe symptoms reported no impact on daily activities on therapy.

Secondary analysisn = 3,136
Sheets et al. Early Symptom Response in Patients With Uncomplicated Urinary Tract Infection Treated With Gepotidacin or Nitrofurantoin: Pooled Analysis From Two Pivotal Phase 3 Studies

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.